

36th ANNUAL SYMPOSIUM ON THE CANNABINOIDS PRELIMINARY PROGRAM

Exhibition and Trade Center of Dijon
3 Bd de Champagne, 21000
Dijon, France

Sunday, June 28, 2026

16:00	Registration (Exhibition and Trade Center of Dijon, 3 Bd de Champagne, 21000, Dijon, France)
18:00 - 20:00	Welcome Reception

Day 1. Monday, June 29, 2026

8:30-8:45	Welcome	
8:45-10:30	Session 1. The Endocannabinoid System: Medicinal Chemistry, Chemical Biology, AI & Drug Discovery	
8:45-9:15	Session Keynote Presentation	Uwe Grether
9:15-9:30	BIOORTHOGONAL PROBES TO VISUALIZE ENDOCANNABINOIDS AND THEIR METABOLISM	Jeroen Punt
9:30-9:45	CHEMICAL PROBES FOR VISUALIZING AND UNLOCKING THE MULTIFACETED ROLE OF MONOACYLGLYCEROL LIPASE	Marc Nazare
9:45-10:00	A NOVEL CB2R-BASED APPROACH TO SUPPRESS LEUKOCYTE GUT-HOMING AND ATTENUATE INFLAMMATION IN CROHN'S DISEASE WITH STABILISED PEPTIDE ANTAGONISTS	David O'Connell
10:00-10:15	UNBIASED IDENTIFICATION OF PUTATIVE CLINICAL BIOMARKERS OF TARGET ENGAGEMENT WITH THE SELECTIVE FATTY ACID-BINDING PROTEIN 5 INHIBITOR ART26.12	Myles Osborn

10:15-10:30	INSIGHTS INTO THE TETRAHYDROPYRIDAZINE MOLECULAR SCAFFOLD CLASS OF PERIPHERAL CB1 ANTAGONISTS FOR THE TREATMENT OF METABOLIC DISORDERS	Malliga Iyer
10:30-11:00	Coffee Break	
11:00-12:00	Session 2. Emerging Topics	
11:00-11:15	INVESTIGATING THE ROLE OF THE ENDOCANNABINOID SYSTEM IN THE PATHOPHYSIOLOGY OF RETINOPATHY OF PREMATURITY	Remi Karadayi
11:15-11:30	IMPACTS OF CO-ADMINISTERED ALCOHOL AND VAPORIZED CANNABIS ON SIMULATED DRIVING ABILITY AND ABUSE LIABILITY	Halle Thomas
11:30-11:45	INHIBITION OF DIAGLYCEROL LIPASE DISRUPTS THE HEAD-TWITCH RESPONSE INDUCED BY PSILOCYBIN	April Contreras
11:45-12:00	HOW DOES CANNABIS USE AFFECT THE BRAIN'S REWARD SYSTEM? A 12-MONTH LONGITUDINAL FMRI STUDY OF ADULTS AND ADOLESCENTS WHO USE CANNABIS AND AGE-MATCHED CONTROLS	Martine Skumlien
12:00-13:00	Presidential Plenary Lecture 1 A DRUGGABLE ACSL4 ISOFORM MOONLIGHTING FUNCTION FACILITATES ENDOCANNABINOID PLASMA-MEMBRANE DIFFUSION AND TUNES CB1 RECEPTOR SIGNALING	Jürg Gertsch
13:00-14:30	Lunch	
14:30-15:45	Session 3. Medicinal Cannabis: Clinical Evidence & Applications	
14:30-14:45	THE CANNABIDIOL FOR ACUTE PSYCHOSOCIAL STRESS AND NAUSEA (CAPSTAN) CLINICAL TRIAL	Zeeta Bawa

14:45-15:00	ACUTE AND LONGER- TERM EFFECTS OF EDIBLE CANNABIS USE OF DIFFERING CANNABINOID RATIOS FOR OLDER ADULTS USING FOR PAIN, SLEEP, AND MOOD PROBLEMS	Angela Bryan
15:00-15:15	PRIMARY RESULTS OF A RANDOMIZED CLINICAL TRIAL OF VAPORIZED CANNABIS VERSUS ORAL OXYCODONE FOR CHRONIC SPINE PAIN	Rachael Rzasa Lynn
15:15-15:30	IMPACTS OF MINOR CANNABINOIDS AND TERPENES ON MENOPAUSE AND PERIMENOPAUSE SYMPTOMS	Matteya Proctor
15:30-15:45	EXAMINING THE PSYCHOLOGICAL AND PHYSIOLOGICAL EFFECTS OF CANNABIGEROL (CBG) IN A DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER CLINICAL TRIAL	Erika Lutz
15:45-16:15	Mary E. Abood ICRS Women in Cannabinoid Research Award Lecture	Cinnamon Bidwell
16:15-16:30	Data Blitz 1	
	A PHASE 1 STUDY TO ASSESS THE SAFETY AND PHARMACOKINETICS OF ART26.12; AN ORALLY DOSED FATTY ACID-BINDING PROTEIN 5 (FABP5) INHIBITOR	Saoirse O'Sullivan
	MACHINE LEARNING METHODS TO INTEGRATE MULTI-OMIC DATA AND IDENTIFY TREATMENT MOLECULAR SIGNATURES IN A PSORIASIS MODEL	Myles Osborn
	UNLOCKING THE ENDOCANNABINOID SYSTEM (ECS) WITH CHEMICAL PROBES	Yelena Mostinski
	CHEMICAL BIOLOGY TOOLS TO STUDY GLYCEROPHOSPHODIESTERASE GDE4 AS A THERAPEUTIC TARGET IN PEDIATRIC NEURAL CANCERS	Aukje Beers

	CANNABINOID SUBTYPE-2 (CB2R) RECEPTOR AGONISTS AS A STRATEGY TO FACE INFLAMMATION-BASED DISEASES: PROMISING IN VIVO EVIDENCE IN ALZHEIMER'S DISEASE AND IN GASTRIC CANCER	Marialessandra Contino
	PERCEPTIONS REGARDING THE USE OF CANNABIS, ALCOHOL, AND TOBACCO DURING PREGNANCY AMONG WOMEN OF CHILD-BEARING AGE	Sharon Casavant
	NAPE-PLD ACTIVATION BY MUSCARINIC RECEPTORS	Jim Wager-Miller
	SEX AND AGE DIFFERENCES IN CANNABIS USE OVER TIME: RESULTS FROM THE NATIONAL SURVEY ON DRUG USE AND HEALTH 2021-2024	Erin Martin
	EVALUATING THE TUMOR ALTERING EFFECTS OF CANNABINOID AGONISTS (ACEA, JWH-133, CP55,940 and CANNABIDIOL) IN OUR BREAST (AT-3 CANCER CELL LINES) CANCER WILD-TYPE (C57BL/6J) MICE MODEL	Josee Guindon
16:30-18:00	Coffee Break/Poster Session 1 *Odd numbered posters will be presented in the first 45 min (16:15) of the poster session and even numbered posters will be presented in the second half (17:15) of the session	
18:00	Free Evening	

Day 2. Tuesday, June 30

8:30-8:45	Opening Remarks	
8:45-9:15	ICRS Mid-Career Award Lecture	Steven Kinsey
9:15-10:00	Session 4. (Endo)Cannabinoids in Neurodegenerative Disorders	
9:15-9:30	NEUROMETABOLIC ASPECTS OF CANNABIDIOL MECHANISMS IN A MITOCHONDRIAL DISEASE MODE	Gunter Van der Walt
9:30-9:45	CHRONIC CANNABIDIOL RESTRUCTURES THE ENDOCANNABINOID LANDSCAPE IN AGED HIV-1 TAT TRANSGENIC MICE	Barkha Yadav-Samudrala
9:45-10:00	CHRONIC NEUROINFLAMMATION IS REQUIRED TO ALLOW CB2-MEDIATED CONTROL OF IN VIVO MICROGLIAL FUNCTION	Julian Romero
10:00-10:30	Session 5. Molecular Pharmacology of (Endo)Cannabinoids	
10:00-10:15	EXPLORING BIASED SIGNALING OF CLINICAL AGONISTS FOR THE CANNABINOID CB2 RECEPTOR WITH A NOVEL FUNCTIONAL MULTIPLEX ASSAY	Lisa de Koning
10:15-10:30	NOVEL, POTENT CB1 ALLOSTERIC MODULATORS	Ruth Ross
10:30-11:00	Coffee break	
11:00-12:00	Session 6. (Endo)Cannabinoids in Neuropsychiatric Disorders	
11:00-11:15	INVESTIGATING THE LINK BETWEEN EARLY LIFE STRESS, SOCIAL STRESS RESPONSE, AND IN-VIVO BRAIN FATTY ACID AMIDE HYDROLASE LEVELS IN INDIVIDUALS WITH SOCIAL ANXIETY DISORDER	Christina Pereira

11:15-11:30	SYT-510, A CLINICAL CANDIDATE FOR A FIRST-IN-CLASS SELECTIVE ENDOCANNABINOID REUPTAKE INHIBITOR, DEMONSTRATE EFFICACY IN MULTIPLE PRECLINICAL CNS DISEASE MODELS AND A FAVORABLE PHASE 1 SAFETY PROFILE	Andrea Chicca
11:30-11:45	A NOVEL CANNABINOID RECEPTOR 1 (CB1) PAM-ANTAGONIST DAMPENS AMPHETAMINE-INDUCED DOPAMINE LEVELS; EVIDENCE OF CB1-MEDIATED INDIRECT MODULATION OF HIGH DA STATES.	Catharine Mielnik
11:45-12:00	THE ROLE OF THE ENDOCANNABINOID SYSTEM IN ALCOHOL USE DISORDER (AUD): NOVEL INSIGHTS FROM A PROSPECTIVE CLINICAL STUDY	Sara Kroll
12:00-13:00	Kang Tsou Memorial Lecture PARKINSON'S DISEASE: FROM GENES TO PERSONALIZED TREATMENTS	Thomas Gasser
13:00-14:30	Lunch	
14:30-15:00	Session 7. (Endo)Cannabinoids in Peripheral Organs: Homeostasis & Dysfunction	
14:30-15:45	ENDOCANNABINOID/CB1R OVERACTIVATION: FANNING THE FLAMES OF LUNG INFLAMMATION IN ALCOHOL USE DISORDER	Resat Cinar
14:45-15:00	MAGL INHIBITION SUPPRESSES PSORIASIFORM INFLAMMATION VIA CB2	Eva Wisniewski
15:00-15:15	INSULIN RESISTANCE AS A KEY DETERMINANT OF ENDOCANNABINOID OVERPRODUCTION IN OBESE VISCERAL ADIPOSE TISSUE	Romain Barbosa
15:15-15:30	MITOCHONDRIA-ASSOCIATED CB1 RECEPTORS ARE NEW PLAYERS IN THE CONTROL OF ENERGY AND GLUCOSE METABOLISM	Camille Allard

15:30-15:45	SPATIALLY RESOLVED PROTEOMIC ANALYSIS OF ENDOCANNABINOID SYSTEM MARKERS IN SALIVARY GLANDS OF PATIENTS WITH SJÖGREN'S SYNDROME	Natalia Malek
15:45-16:15	Session Keynote Presentation	Pal Pacher
16:15-16:30	Data blitz 2	
	EVALUATING THE EFFECT OF CANNABIDIOL ON SLEEP QUALITY IN PATIENTS WITH MULTIPLE SCLEROSIS USING 15 AGGREGATED N-OF-1 TRIALS	Bo Saals
	HEALTH IMPACT OF NEWLY STARTING MEDICINAL CANNABIS USE AMONG ADULTS WITH ANXIETY AND/OR PTSD – A LONGITUDINAL OBSERVATIONAL STUDY	Ryan Vandrey
	FIRST REPORT OF OFF-LABEL CBD-RICH BROAD-SPECTRUM CANNABIS THERAPY IN RUBINSTEIN-TAYBI SYNDROME: CLINICAL OUTCOMES FROM A RARE GENETIC DISORDER	Micheline Donato
	CHRONIC CBD MITIGATES AGE-ASSOCIATED DYSREGULATION OF NEUROINFLAMMATION IN A MOUSE MODEL OF GULF WAR ILLNESS	Kwang-Mook Jung
	CHRONIC FAAH INHIBITION MODULATES NEUROINFLAMMATION IN AD MICE	M Teresa Grande
	DIFFERENTIAL REGULATION OF ERK1/2 AND MKP-3 BY JWH-133 AND 2-AG REVEALS LIGAND-BIASED CANNABINOID TYPE 2 RECEPTOR SIGNALING IN MICROGLIA	Kaitlyn Partridge
	TUBEROUS SCLEROSIS COMPLEX-ASSOCIATED NEUROPSYCHIATRIC DISORDERS (TAND) OUTCOMES FOLLOWING ADJUNCTIVE CANNABIDIOL TREATMENT: 6-MONTH INTERMEDIATE ANALYSIS OF THE EPICOM TRIAL	Stevie Roszkowski
	ENDOCANNABINOID MODULATION OF CUE-EVOKED FEAR IN A MOUSE MODEL OF ELEVATED DOPAMINE TONE	Stefan Vislavski

	CARDIAC SURGERY-INDUCED ACUTE KIDNEY INJURY IN PEDIATRIC PATIENTS DISPLAYS EARLY SYSTEMIC ENDOCANNABINOID SYSTEM ELEVATION	Ariel Rothner
	MONLUNABANT : A BETTER STRATEGY TO TACKLE TYPE 1 DIABETES?	Elise Wreven
16:30-18:00	Poster Session 2	
	*Odd numbered posters will be presented during the first 45 min (15:45) of the poster session and even numbered posters will be presented in the second half (16:45) of the poster session	
18:00	Free Evening	

Day 3. Wednesday, July 1

8:30-8:45	Opening remarks	
8:45-9:15	ICRS Lifetime Achievement Award Lecture	Brian Thomas
9:15-10:00	Session 8. New Insights into Brain Signaling via (Endo)Cannabinoids	
9:15-9:30	DISSECTING THE ROLE OF CB1R EXPRESSING GABAERGIC INTERNEURONS IN THE BASOLATERAL AMYGDALA DURING FEAR EXTINCTION	Ozge Gunduz-Cinar
9:30-9:45	ANALYZING NATURAL MOUSE BEHAVIOR USING MACHINE LEARNING AND POSE ESTIMATION: IMPACT OF THC AND ROLE OF ENDOCANNABINOID SIGNALING	Nephi Stella
9:45-10:00	GLUTAMATERGIC SIGNALING ALTERATIONS IN CA1 PYRAMIDAL NEURONS MEDIATE THC INDUCED MEMORY IMPAIRMENT	Armin Kouchaeknejad
10:00-10:30	Session 9. (Endo)Cannabinoids in Nociception & Pain	
10:00-10:15	KLS 13019: A SYNTHETIC CBD ANALOGUE THAT REVERSES SYMPTOMS AND PRESERVES CHEMOTHERAPEUTIC EFFICACY IN NOVEL TRANSLATIONAL MODELS OF CIPN	Michael Ippolito
10:15-10:30	CANNABIDIOL FOR SPINAL CORD INJURY CHRONIC NEUROPATHIC PAIN: A RANDOMIZED CLINICAL TRIAL	Iain McGregor
10:30-11:00	Coffee break	
11:00-11:15	INHIBITION OF FATTY ACID BINDING PROTEIN 5 ALLEVIATES NEUROPATHIC PAIN FOLLOWING SPINAL CORD INJURY IN MICE	Martin Kaczocha

11:15-11:30	Δ^9 -Tetrahydrocannabinol and Cannabidiol synergistically alleviate hyperalgesia in a humanized mouse model of sickle cell disease	Alex Mabou Tagne
11:30-11:45	Cannabidiol attenuates chemotherapy-induced peripheral neuropathic pain through a mechanism that requires the enzyme N-acyl phosphatidylethanolamine-specific phospholipase D (NAPE-PLD)	Carlos Henrique Alves Jesus
11:45-12:00	THC-induced behavior, physiology, and withdrawal effects are exacerbated by RGS12 deletion	Antonio Reck
12:00-13:00	Mechoulam Award Lecture	Andrea Hohmann
13:00-13:30	Business Meeting	
13:30	Boxed Lunch/Free Afternoon	

Day 4. Thursday, July 2

8:30-8:45	Opening remarks	
8:45-9:15	ICRS Early Career Award Lecture	Tory Spindle
9:15-10:30	Session 10. Cannabis Exposure in Translational Models (Animal and Human Studies)	
9:15-9:30	CHRONIC VOLUNTARY CONSUMPTION OF CANNABINOIDS IN C57BL/6 MICE	Alayna Jones
9:30-9:45	DELTA-9-TETRAHYDROCANNABINOL-SPARING EFFECTS OF CANNABIGEROL: A PLACEBO-CONTROLLED HUMAN LABORATORY STUDY	Elisa Pabon
9:45-10:00	DETECTION OF PRENATAL CANNABIS EXPOSURE: IS MECONIUM A RELIABLE BIOMARKER?	Virginie Bouchard
10:00-10:15	ADOLESCENT THC EXPOSURE INDUCES A MONOCYTE PHENOTYPE PRIMED FOR ENHANCED IMMUNE RESPONSE LATER IN LIFE	Rodrigo Klein
10:15-10:30	CANNABIS EFFECTS ON OPIOID SELF-ADMINISTRATION: PILOT STUDY IN NON-DEPENDENT, OCCASIONAL OPIOID USERS	Shanna Babalonis
10:30-11:00	Coffee break	
11:00-12:00	Session 11. (Endo)Cannabinoids in Neurodevelopment	
11:00-11:15	EVIDENCE OF BRAIN INJURY AND DYSREGULATION OF HOMEOSTATIC INFLAMMATORY MEDIATORS IN A PRECLINICAL MODEL OF PRENATAL CANNANOID EXPOSURE	Elise Weerts

11:15-11:30	OMEGA-3 SUPPLEMENTATION COUNTERACTS PERSISTENT BEHAVIOURAL AND GUT-BRAIN ALTERATIONS PRODUCED BY ADOLESCENT EDIBLE THC EXPOSURE	Marieka DeVuono
11:30-11:45	CANNABIDIOL EFFECTS UPON EXECUTIVE FUNCTION IN A CLINICAL TRIAL OF PEDIATRIC EPILEPSY AND COMORBID ANXIETY	Jay Salpekar
11:45-12:00	DOES PRENATAL/PERINATAL ACETAMINOPHEN TREATMENT INHIBIT DIACYLGLYCEROL LIPASE ALPHA TO CAUSE ASD-LIKE BEHAVIORS IN MICE?	Michaela Dvorakova
12:00-13:00	Presidential Plenary Lecture 2 SHINING FLUORESCENT LIGHT ON COLORFUL CANNABINOID SIGNALING	Istvan Katona
13:00-14:30	Lunch	
14:30-15:30	Session 12. (Endo)Cannabinoids in Energy Metabolism & Cardiovascular Health	
14:30-14:45	INTERIM ANALYSIS OF THE PHASE 2 CANCER APPETITE RECOVERY STUDY (CARES) EVALUATING ART27.13, A PERIPHERALLY SELECTIVE CANNABINOID AGONIST	Saoirse O'Sullivan
14:45-15:00	CANNABINOID RECEPTOR β -ARRESTIN SIGNALING ALTERS CYTOKINE CONTROL OF METABOLIC AND INFLAMMATORY PATHWAYS	Gergő Szanda
15:00-15:15	CB2 RECEPTOR ACTIVATION DRIVES MITOCHONDRIAL METABOLIC STRESS AND LIMITS AGGRESSIVE POTENTIAL IN COLORECTAL CANCER CELLS	Daniela Esposito
15:15-15:30	NEW THERAPEUTIC TARGETS FOR HEPATIC FIBROSIS IN MASLD: THE SGLT2 COTRANSPORTER AND THE CANNABINOID-1 RECEPTOR. NEW THERAPEUTIC TARGETS FOR HEPATIC FIBROSIS IN MASLD: THE SGLT2 COTRANSPORTER AND THE CANNABINOID-1 RECEPTOR	Maéva Lorient

15:30-15:45	Data Blitz 3	
	AGE MEDIATES EFFECT OF CB1 RECEPTOR DELETION ON FINE MOTOR LEARNING, SPINE DYNAMICS, AND NEURON-MICROGLIA PROXIMITY	Joanna Komorowska-Müller
	DISTINCT IN VIVO SHORT-TERM PLASTICITY OF HIPPOCAMPAL CCK- AND PV-EXPRESSING BASKET CELL SYNAPSES	Barna Dudok
	THE SELECTIVE FATTY ACID BINDING PROTEIN 5 INHIBITOR ART26.12 RELIEVES OSTEOARTHRITIS PAIN	Martin Kaczocha
	DUALSTERIC CB1 POSITIVE ALLOSTERIC MODULATOR/CB2 AGONIST GAT1102 DISPLAYS BROAD SPECTRUM ANALGESIC EFFICACY WITHOUT PRODUCING CANNABIMIMETIC EFFECTS	Jonah Wirt
	IMPACT OF CANNABIS USE FREQUENCY ON THE ANALGESIC EFFECTS OF SMOKED CANNABIS	Alisha Eversole
	EFFECTS OF CHRONIC CANNABIS USE ON STRESS-INDUCED NEURAL AND IMMUNE RESPONSES IN RATS	Augustine Attah
	CHRONIC DELTA-9-TETRAHYDROCANNABINOL EXPOSURE DURING ADOLESCENCE PRODUCES SELECTIVE BEHAVIORAL ABNORMALITIES IN ADULT NONHUMAN PRIMATES	Brian Kangas
	THE EFFECT OF IN UTERO EXPOSURE TO THC ON THE DEVELOPMENT OF MIDBRAIN DOPAMINERGIC NEURONS	Susanne Hazenberg
	EFFECTS OF ACUTE CANNABIS USE ON METABOLISM: A HUMAN METABOLOMICS STUDY	Jost Klawitter
	CORRELATION BETWEEN BLOOD AND URINE CANNABINOIDS AND SUB-CLINICAL CARDIOVASCULAR BIOMARKERS IN HEALTHY YOUNG ADULTS IN THE HERBAL HEART STUDY	Amrit Baral
15:45-17:15	<p align="center">Poster Session 3</p> <p>*Odd numbered posters will be presented during the first 45 min (15:45) of the poster session and even numbered posters will be presented in the second half (16:30) of the poster session</p>	
19:00	<p align="center">Gala Dinner Banquet</p>	